Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Tumor cells can evade immune detection through the overactivation of the programmed cell death protein-1 (PD-1) / programmed death-ligand 1 (PD-L1) pathway.
• This pathway binding inhibits T-cell proliferation and anticancer activity, limiting immune surveillance within the tumor microenvironment (TME).

Purpose of the Study:

• To explore the role of the PD-1/PD-L1 pathway in tumor immune evasion.
• To highlight the potential of PD-1/PD-L1 inhibitors in cancer immunotherapy, particularly for gastrointestinal (GI) cancers.

Main Methods:

• Review of the molecular mechanisms of PD-1/PD-L1 pathway activation in cancer.
• Analysis of the clinical implications of PD-1/PD-L1 immune checkpoint inhibitors.

Main Results:

• The PD-1/PD-L1 pathway acts as a critical immune checkpoint, enabling tumors to suppress anti-tumor immune responses.
• PD-1/PD-L1 inhibitors have emerged as a significant advancement in cancer immunotherapy.

Conclusions:

• Targeting the PD-1/PD-L1 pathway can restore T-cell surveillance and enhance the body's anti-tumor immunity.
• Optimizing the clinical application of PD-1/PD-L1 inhibitors holds significant promise for improving survival rates in GI cancer patients.